首页> 外文期刊>The journal of clinical hypertension. >Aliskiren: A Potential Antiarrhythmic Drug?
【24h】

Aliskiren: A Potential Antiarrhythmic Drug?

机译:Aliskiren:潜在的抗心律不齐药物?

获取原文
获取原文并翻译 | 示例
           

摘要

Aliskiren is the first oral direct renin inhibitor available, and its current licensed indication is essential hypertension. As current guidelines indicate, the available evidence justifies its use in hypertension, particularly in combination with other agents.1 In fact, several studies have demonstrated that aliskiren effectively reduces both systolic and diastolic blood pressure values in the whole hypertensive population, including those at higher risk with a good tolerability profile.~2 However, emerging evidence suggests that aliskiren may have some antiarrhythmic effects beyond blood pressure control.
机译:Aliskiren是第一个可用的口服直接肾素抑制剂,其当前许可的适应症是原发性高血压。正如目前的指南所表明的那样,现有证据证明其可用于高血压,特别是与其他药物联合使用。1实际上,数项研究表明,阿利吉仑可有效降低整个高血压人群(包括那些高血压人群)的收缩压和舒张压值。 〜2然而,新的证据表明阿利吉仑可能具有一些超出血压控制的抗心律失常作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号